A physical exam may be performed, and we may recommend lab work, such as blood sugar, cholesterol, and kidney function tests, to establish a baseline before starting treatment
Contact [email protected] for any questions or corrections.
Design, Setting, and Participants In this retrospective cohort study, 125 474 adults with overweight or obesity newly initiated treatment with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023, with a baseline body mass index of 27 or more, an available weight measurement within 60 days before initiation, and regular care in the year before initiation were identified using electronic health record data from a collective of US health care systems
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischaemic optic neuropathy (NAION)
You dont have to go it alone Whether youre just beginning or returning to fitness with support from GLP-1 medication, remember: youre not the only one
